TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
7.26B
Enterprise Value 3
35.87B
Trailing P/E
N/A
Forward P/E 1
2.77
PEG Ratio (5 yr expected) 1
-0.95
Price/Sales (ttm)
0.41
Price/Book (mrq)
0.53
Enterprise Value/Revenue 3
2.02
Enterprise Value/EBITDA 6
8.21

Trading Information

Stock Price History

Beta (3Y Monthly) 2.42
52-Week Change 3-68.69%
S&P500 52-Week Change 36.61%
52 Week High 324.47
52 Week Low 36.07
50-Day Moving Average 37.17
200-Day Moving Average 39.60

Share Statistics

Avg Vol (3 month) 319.85M
Avg Vol (10 day) 312.43M
Shares Outstanding 51.09B
Float 1B
% Held by Insiders 13.95%
% Held by Institutions 163.54%
Shares Short (Sep 30, 2019) 479.28M
Short Ratio (Sep 30, 2019) 43.27
Short % of Float (Sep 30, 2019) 4N/A
Short % of Shares Outstanding (Sep 30, 2019) 47.26%
Shares Short (prior month Aug 30, 2019) 468.59M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Dec 12, 2017
Ex-Dividend Date 4Nov 27, 2017
Last Split Factor (new per old) 21/2
Last Split Date 3Jul 1, 2004

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -21.94%
Operating Margin (ttm)14.77%

Management Effectiveness

Return on Assets (ttm)2.59%
Return on Equity (ttm)-24.31%

Income Statement

Revenue (ttm)17.72B
Revenue Per Share (ttm)16.76
Quarterly Revenue Growth (yoy)-7.70%
Gross Profit (ttm)8.3B
EBITDA 4.37B
Net Income Avi to Common (ttm)-4.01B
Diluted EPS (ttm)-3.79
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.16B
Total Cash Per Share (mrq)1.98
Total Debt (mrq)29.3B
Total Debt/Equity (mrq)192.12
Current Ratio (mrq)0.95
Book Value Per Share (mrq)12.93

Cash Flow Statement

Operating Cash Flow (ttm)673M
Levered Free Cash Flow (ttm)2.19B